The customer would like the run data file investigated to determine a possible cause for the elevated white blood cell (wbc) content in the platelet product.Unit id #: (b)(6).There was not a transfusion recipient or patient involved at the time of the residual wbc testing, therefore no patient information is reasonably known at the time of the event.This product is not available within the us, but this report is being filed due to an alleged failure that could occur on a similarly marketed device platform cleared for use by the fda.Terumo bct is awaiting return of the disposable set for evaluation.
|
This report is being filed to provide additional information in h.3, h.6 and h.11.Investigation: two used platelet bags, one containing platelets, the other emptied, were received for investigation.Visual inspection noted no defects or abnormalities in the bags or the attached returned tubing.The run data file (rdf) was analyzed for this event.The trima accel system has several methods for detection of possible wbc contamination, however, as the trima accel system cannot count the cells entering the platelet product bag, the rbc detector signals must see a significant change in the reflectance values to notify the operator of an lrs chamber saturation and to count the wbcs in the platelet product.Possible factors that could contribute to a leukoreduction failure include, but are not limited to: - flow adjustments that reduce the inlet flow, and therefore the flow through the lrs chamber.When the flow through the lrs chamber is greatly reduced, the risks of contamination of leukocytes (wbcs) can be increased.- numerous access pressure pauses occurring during a procedure.Although the trima accel system is typically robust against numerous access pressure pauses, it is possible the a high number of access pressure pauses occurring during a procedure could disrupt the steady-state of the lrs chamber.- a difference between the entered and actual donor platelet precounts may contribute to a leukoreduction failure.With a lower than actual entered platelet precount, more blood volume is unnecessarily processed to meet the targeted platelet yield, possibly increasing the risks for wbc contamination.- related to donor specific blood characteristics that may challenge the trima accel leukoreduction system the device history records (dhr) were reviewed for this lot.There were no events noted in the dhr that would have contributed to the elevated wbc count experienced by the customer.Investigation is still in process, a follow-up report will be provided.
|
The customer would like the run data file investigated to determine a possible cause for the elevated white blood cell (wbc) content in the platelet product.Unit id #: (b)(6) there was not a transfusion recipient or patient involved at the time of the residual wbc testing, therefore no patient information is reasonably known at the time of the event.This product is not available within the us, but this report is being filed due to an alleged failure that could occur on a similarly marketed device platform cleared for use by the fda.
|